The insulin import forecast to the US indicates a steady yet minimal decline from 2024 to 2028. The year-on-year variations showcase a slight decrease annually, with the value expected to dip progressively from 6.41 thousand kilograms in 2024 to 6.36 thousand kilograms in 2028. In 2023, the import volume stood at a similar level, suggesting maintained but slightly reduced import activity over the forecast period. The five-year CAGR emphasizes a marginal negative trend, highlighting the decrease in import volumes.
Future trends to watch for include:
- Impact of domestic insulin production to offset imports.
- Changes in global trade relations affecting supply chains.
- Technological advancements in insulin manufacturing.
- Shifts in regulatory policies influencing import volumes.
